In less than one week, Innovent Biologics Inc. has seen two NDAs for non-small-cell lung cancer accepted for review by China’s National Medical Products Administration, and both are firsts for China. The NDA for IBI-351 under priority review marks China’s first NDA for a KRAS G12C inhibitor, and the NDA for taletrectinib is the first global submission for the ROS1 inhibitor.
Innovent and AnHeart Announce Interim Data from Phase 2 Trial of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes.
Share:
HANGZHOU, China and NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) AnHeart Therapeutics Co., Ltd. ( AnHeart ), a clinical stage oncology company focused on underserved patients in global markets, announces an upcoming presentation of an abstract selected for poster presentation from its ongoing Phase II trial of taletrectinib in ROS1 fusion positive Non-Small Cell Lung Cancer (NSCLC) (NCT04395677) at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting being held virtually on June 4-8, 2021. Details on the abstract and a corresponding poster presentation are shown below.
Abstract Number: 9066
Abstract Title:
Taletrectinib (AB-106; DS-6051b) in metastatic non-small cell lung cancer (NSCLC) patients with ROS1 fusion: Preliminary results of TRUST.
AnHeart Announces Upcoming Presentation of Preliminary Results from Phase II Trial of Taletrectinib in ROS1+ NSCLC at the ASCO 2021 Virtual Meeting biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.